2022 / 06

Next Paper
DOI: 10.24075/brsmu.2022.071

ORIGINAL RESEARCH

Efficacy of favipiravir and molnupiravir against novel SARS-CoV-2 variants in vitro and in vivo

Siniavin AE1,2, Russu LI1, Vasina DV1, Shidlovskaya EV1, Kuznetsova NA1, Gushchin VA1,3, Gintsburg AL1,4
About authors

1 Gamaleya National Research Center for Epidemiology and Microbiology, Moscow, Russia

2 Shemyakin and Ovchinnikov Institute of Bioorganic Chemistry, Moscow, Russia

3 Lomonosov Moscow State University, Moscow, Russia

4 Sechenov University, Moscow, Russia

Correspondence should be addressed: Andrey E. Sinyavin
Gamalei, 16, Moscow, 123098, Russia; ur.xednay@39isyerdna

About paper

Funding: the study was supported by the Russian Ministry of Health, grant № 121111200070-4 (P16).

Acknowledgments: the authors would like to thank the staff of N.I. N.F. Gamaleya A. Zakharova and T. Remizov for organizing the supply of reagents for the study.

Author contribution: Sinyavin AE — design of the experiment, study of antiviral activity, data analysis, writing the text; Russu LI — work with the virus and animals; Vasina DV — work with animals; Shidlovskaya EV, Kuznetsova NA — PCR analysis, data processing; Gushchin VA — research supervision, text editing; Gunzburg AL — approval of the research concept.

Compliance with ethical standards: the study was approved by the ethics committee of the Federal State Budgetary Institution “N.N. N.F. Gamaleya" of the Ministry of Health of the Russian Federation (protocol № 27 of June 6, 2022); conducted in compliance with the principles of the Declaration of Helsinki of the World Medical Association.

Received: 2022-12-05 Accepted: 2022-12-20 Published online: 2022-12-31
|
No data available...